CAS: 942183-80-4; (R)-1-(2-Oxo-2-(4-(4-(Pyrimidin-2-yl)Phenyl)Piperazin-1-yl)Ethyl)-N-(3-(Pyridin-4-yl)-1H-Indazol-5-yl)Pyrrolidine-3-Carboxamide
该化合物是一个小分子抑制剂,主要以选择性抑制外生体活性蛋白动脉(MAPK)路径而闻名,具体针对外细胞信号调节性动脉(ERK)信号级联;该化合物在治疗以异常ERK信号为特征的各种恶性肿瘤方面的潜在治疗应用引起了癌症研究的注意;SCH772984显示出ERK1和ERK2的高度特殊性,它们是涉及细胞扩散和生存的MAPK路径的关键组成部分;该化合物的特点是有机溶性中度和生理条件下的稳定性;在临床前研究中,SCH772984显示出抑制各种癌症模型肿瘤生长的功效,使其成为目标癌症疗法进一步发展的感兴趣对象;其化学结构和特性促进了其作为研究工具的作用,以了解与IRK相关的信号机制和开发新型治疗战略.
- 英文名称(R)-1-(2-Oxo-2-(4-(4-(Pyrimidin-2-yl)Phenyl)Piperazin-1-yl)Ethyl)-N-(3-(Pyridin-4-yl)-1H-Indazol-5-yl)Pyrrolidine-3-Carboxamide
- 中文名称(R)-1-(2--2-氧(4-(4-(嘧啶-2-基)苯基)对二氮己环-1-基)乙基)-N-(3-(吡啶-4-基)-1H--5INDAZOL-基)吡咯烷-3-甲酰胺
- IUPAC名称(R)-1-(2-oxo-2-(4-(4-(pyrimidin-2-yl)phenyl)piperazin-1-yl)ethyl)-N-(3-(pyridin-4-yl)-1H-indazol-5-yl)pyrrolidine-3-carboxamide
- 其它别名3-Pyrrolidinecarboxamide, 1-[2-Oxo-2-[4-[4-(2-Pyrimidinyl)Phenyl]-1-Piperazinyl]Ethyl]-N-(3-Phenyl-1H-Indazol-5-yl)-, (3R)- ; (3R)-1-[2-Oxo-2-[4-(4-Pyrimidin-2-Ylphenyl)Piperazin-1-Yl]Ethyl]-N-(3-Pyridin-4-Yl-1H-Indazol-5-yl)Pyrrolidine-3-Carboxamide ; Sc
- CAS编号942183-80-4
- MFCD编号:MFCD28144700
- 分子式:C33H33N9O2分子量:587.69
- 产品CID: 1990578
- 相似结构搜索
- InChIKey: HDAJDNHIBCDLQF-RUZDIDTESA-N
- HDAJDNHIBCDLQF-RUZDIDTESA-N
- 计算化学: 氢键受体数8.0氢键供体数2.0可旋转键数7.0
物理性质
- 熔点>214°C (分解)
- 沸点857.3±65.0 °C at 760 mmHg
- 闪点472.3±34.3 °C
- 密度1.4±0.1 g/cm3
- pKa:12.05±0.40(预测)
- PSA:126.73
- LogP:2.1
- 折射率1.694
- 蒸汽压0.0±3.2 mmHg at 25°C
- 溶解性DMSO (Slightly)
- 外观形态淡黄色固体
- 储存条件冰箱
- 产品应用该化合物是ERK1/2的新型选择性ATP竞争抑制器,展示了对存放RAS或BRAF突变的癌症细胞的强大活动;它禁止ERK子质的磷酸化,如P90 肋骨S6 流动酶(RTK, T359/S363)和ERK活化循环内残留物的亚光伏成像,以依赖剂量的方式进行;它抑制ABRAF-或MEK抗抑制剂模型中的MAPK信号和细胞扩散;并在容许剂量的情况下诱发基因模型的肿瘤回归.
合成工艺路线路线简述
- 1692-15-5 + 942189-38-0 = 942183-80-4
反应条件:1.1 Reagents: Sodium Carbonate Catalysts: [1,1′-Bis(Diphenylphosphino)Ferrocene]Dichloropalladium Solvents: 1,2-Dimethoxyethane,Water; 600 S,120 °C; Cooled1.2 Reagents: Water; Rt
标题:Polycyclic Indazole Derivatives That Are Erk Inhibitors And Their Preparation,Pharmaceutical Compositions And Use In The Treatment Of Cancer
参考文献:United States]
= 942183-80-4 [标题:Reaction Conditions
标题:Polycyclic Indazole Derivatives That Are Erk Inhibitors And Their Preparation,Pharmaceutical Compositions And Use In The Treatment Of Cancer
参考文献:World Intellectual Property Organization
海关参考信息
- 2912110000-甲醛
2912120000-乙醛
2921211000-乙二胺
2924191000-二甲基甲酰胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:CN-108379591-B
优先权日:2018-04-03
标 题 :Synthesis of Immune Agonist Targeting Compounds and Their Applications
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24. 3(7):719-21. doi: 10.1158/2159-8290.CD-13-0245.
13:194. doi: 10.1186/1476-4598-13-194. Erratum in: Mol Cancer. 2015 Jul 02;14:128. doi: 10.1186/s12943-015-0393-2.
4: Foda ZH, Seeliger MA. Kinase inhibitors: an allosteric add-on. Nat Chem Biol. 2014 Oct;10(10):796-7. doi: 10.1038/nchembio.1630. Epub 2014 Sep 7. 10(10):853-60. doi: 10.1038/nchembio.1629. Epub 2014 Sep 7.
合成参考文献
参考文献:10.1016/j.jid.2017.01.013
摘要:Trousil S, Chen S, Mu C, Shaw FM, Yao Z, Ran Y, Shakuntala T, Merghoub T, Manstein D, Rosen N, Cantley LC, Zippin JH, Zheng B. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. Journal of Investigative Dermatology. 2017 May;137(5):1135–43. doi: 10.1016/j.jid.2017.01.013.
📝 需求与反馈
尽可能描述清楚需求与问题信息
